[18F]FDG uptake of bone marrow on PET/CT for predicting distant recurrence in breast cancer patients after surgical resection

EJNMMI Research

Table 1 Characteristics of 345 patients

Characteristics		Number (%)	Median (range)
Age (years)			51 (30–85)
Menopausal status	Premenopausal	146 (42.3%)
Menopausal status	Postmenopausal	199 (57.7%)
Histopathology	Invasive ductal carcinoma	307 (89.0%)
Histopathology	Invasive lobular carcinoma	38 (11.0%)
T stage	T1	158 (45.8%)
	T2	151 (43.8%)
	T3	24 (7.0%)
	T4	12 (3.5%)
N stage	N0	223 (64.6%)
	N1	68 (19.7%)
	N2	29 (8.4%)
	N3	25 (7.3%)
Tumor size (cm)			2.0 (0.4–15.0)
Histologic grade	Grade 1	82 (23.8%)
	Grade 2	173 (50.1%)
	Grade 3	90 (26.1%)
Estrogen receptor status	Positive	258 (74.8%)
Estrogen receptor status	Negative	87 (25.2%)
Progesterone receptor status	Positive	212 (61.4%)
Progesterone receptor status	Negative	133 (38.6%)
HER2 status	Positive	176 (51.0%)
HER2 status	Negative	169 (49.0%)
Ki67 expression status	Positive (≥ 14%)	230 (66.7%)
Ki67 expression status	Negative (< 14%)	115 (33.3%)
WBC (× 10¹² cells/L)			6.36 (2.47–17.56)
NLR			1.66 (0.29–11.36)
PLR			120.20 (20.63–600.00)
Maximum SUV of primary tumor			4.10 (1.10–37.90)
MTV of primary tumor (cm³)			1.14 (0.0–528.58)
TLG of primary tumor (g)			3.45 (0.0–3311.99)
BM SUV			1.61 (0.62–2.73)
BLR			0.76 (0.35–1.54)
Neoadjuvant chemotherapy	Yes	48 (13.9%)
Neoadjuvant chemotherapy	No	297 (86.1%)
Adjuvant treatment	CTx+RTx+HTx	165 (47.8%)
	RTx+HTx	100 (29.0%)
	CTx+HTx	19 (5.5%)
	CTx+RTx	5 (1.4%)
	HTx	28 (8.1%)
	CTx	20 (5.8%)
	RTx	3 (0.9%)
	No	5 (1.4%)

HER2 human epidermal growth factor receptor 2, WBC white blood cell, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SUV standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, BM bone marrow, BLR bone marrow-to-liver uptake ratio, CTx chemotherapy, RTx radiotherapy, HTx hormonal therapy